Entry Point Capital, LLC Acadia Pharmaceuticals Inc Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 26,022 shares of ACAD stock, worth $527,986. This represents 0.22% of its overall portfolio holdings.
Number of Shares
26,022
Previous 10,970
137.21%
Holding current value
$527,986
Previous $168,000
183.93%
% of portfolio
0.22%
Previous 0.1%
Shares
5 transactions
Others Institutions Holding ACAD
# of Institutions
316Shares Held
164MCall Options Held
855KPut Options Held
350K-
Baker Bros. Advisors LP New York, NY42.9MShares$870 Million8.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.9MShares$283 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$245 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.71MShares$177 Million2.61% of portfolio
-
Morgan Stanley New York, NY7.3MShares$148 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.28B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...